Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

James Carmichael

Showing results (31-40 of 63) with videos related to

Pageof 7
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 19, 2005
Phase III trial of epirubicin plus paclitaxel compared with epirubicin plus cyclophosphamide as first-line chemotherapy for metastatic breast cancer: United Kingdom National Cancer Research Institute trial AB01Ruth E Langley, James Carmichael, Alison L Jones, et al.
Medical Engineering & Physics|October 20, 2006
A speech-controlled environmental control system for people with severe dysarthriaMark S Hawley, Pam Enderby, Phil Green, et al.
BMC Cancer|July 20, 2004
Phase I/II study of first-line irinotecan combined with 5-fluorouracil and folinic acid Mayo Clinic schedule in patients with advanced colorectal cancerThomas Kuehr, Paul Ruff, Bernardo L Rapoport, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 18, 2008
A phase I and pharmacokinetic study of ixabepilone in combination with Carboplatin in patients with advanced solid malignanciesRuth Plummer, Penella Woll, David Fyfe, et al.
Proteomics|September 16, 2003
A prototype methodology combining surface-enhanced laser desorption/ionization protein chip technology and artificial neural network algorithms to predict the chemoresponsiveness of breast cancer cell lines exposed to Paclitaxel and Doxorubicin under in vitro conditionsShahid Mian, Graham Ball, Jo Hornbuckle, et al.
Cancer Chemotherapy and Pharmacology|April 14, 2011
The effect of different etiologies of hepatic impairment on the pharmacokinetics of gefitinibJiri Horak, Jeff White, Adrian L Harris, et al.
Transactions. Edinburgh Obstetrical Society|April 4, 2018
Discussion-Should Antiseptic Vaginal Douching Be Made a Routine Practice in the PuerperiumJ Halliday Croom, James Ritchie, James Carmichael, et al.
Investigational New Drugs|January 15, 2013
Evaluation of the pharmacodynamics and pharmacokinetics of the PARP inhibitor olaparib: a phase I multicentre trial in patients scheduled for elective breast cancer surgeryNigel Bundred, Janis Gardovskis, Janusz Jaskiewicz, et al.
Breast Cancer Research : BCR|September 26, 2013
Phase I trial of the oral PARP inhibitor olaparib in combination with paclitaxel for first- or second-line treatment of patients with metastatic triple-negative breast cancerRebecca A Dent, Geoffrey J Lindeman, Mark Clemons, et al.
Gan to Kagaku Ryoho. Cancer & Chemotherapy|April 30, 2004
[Anti angiogenesis]Hideyuki Akaza, Masayuki Nakagawa, Takashi Tsuruo, et al.
Pageof 7

Showing results (31-40 of 63) with videos related to

Sort By:
Pageof 7
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 19, 2005
Phase III trial of epirubicin plus paclitaxel compared with epirubicin plus cyclophosphamide as first-line chemotherapy for metastatic breast cancer: United Kingdom National Cancer Research Institute trial AB01Ruth E Langley, James Carmichael, Alison L Jones, et al.
Medical Engineering & Physics|October 20, 2006
A speech-controlled environmental control system for people with severe dysarthriaMark S Hawley, Pam Enderby, Phil Green, et al.
BMC Cancer|July 20, 2004
Phase I/II study of first-line irinotecan combined with 5-fluorouracil and folinic acid Mayo Clinic schedule in patients with advanced colorectal cancerThomas Kuehr, Paul Ruff, Bernardo L Rapoport, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 18, 2008
A phase I and pharmacokinetic study of ixabepilone in combination with Carboplatin in patients with advanced solid malignanciesRuth Plummer, Penella Woll, David Fyfe, et al.
Proteomics|September 16, 2003
A prototype methodology combining surface-enhanced laser desorption/ionization protein chip technology and artificial neural network algorithms to predict the chemoresponsiveness of breast cancer cell lines exposed to Paclitaxel and Doxorubicin under in vitro conditionsShahid Mian, Graham Ball, Jo Hornbuckle, et al.
Cancer Chemotherapy and Pharmacology|April 14, 2011
The effect of different etiologies of hepatic impairment on the pharmacokinetics of gefitinibJiri Horak, Jeff White, Adrian L Harris, et al.
Transactions. Edinburgh Obstetrical Society|April 4, 2018
Discussion-Should Antiseptic Vaginal Douching Be Made a Routine Practice in the PuerperiumJ Halliday Croom, James Ritchie, James Carmichael, et al.
Investigational New Drugs|January 15, 2013
Evaluation of the pharmacodynamics and pharmacokinetics of the PARP inhibitor olaparib: a phase I multicentre trial in patients scheduled for elective breast cancer surgeryNigel Bundred, Janis Gardovskis, Janusz Jaskiewicz, et al.
Breast Cancer Research : BCR|September 26, 2013
Phase I trial of the oral PARP inhibitor olaparib in combination with paclitaxel for first- or second-line treatment of patients with metastatic triple-negative breast cancerRebecca A Dent, Geoffrey J Lindeman, Mark Clemons, et al.
Gan to Kagaku Ryoho. Cancer & Chemotherapy|April 30, 2004
[Anti angiogenesis]Hideyuki Akaza, Masayuki Nakagawa, Takashi Tsuruo, et al.
Pageof 7